The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia

There are currently no regulatory approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). One possibility is that trial methodology itself is hindering their development. Emerging evidence suggests that patients with schizophrenia may show limited benefit f...

Full description

Saved in:
Bibliographic Details
Published in:Front Psychiatry
Main Authors: Cotter, Jack, Barnett, Jennifer H., Granger, Kiri
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2019
Subjects:
Psychiatry
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6743013/
https://ncbi.nlm.nih.gov/pubmed/31551837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpsyt.2019.00648
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items